和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

未开盘 12-20 16:08:10

4.340

-0.070

-1.59%

最高4.410	最低4.310	成交量62.10万
今开4.410	昨收4.410	日振幅2.27%
总市值29.51亿	流通市值29.51亿	总股本6.80亿
成交额270.94万	换手率0.09%	流通股本6.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":4.34,"timestamp":1734682090015,"preClose":4.41,"halted":0,"volume":621000,"delay":0,"floatShares":680000000,"shares":680000000,"eps":-0.7108012,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.07,"latestTime":"12-20 16:08:10","open":4.41,"high":4.41,"low":4.31,"amount":2709370,"amplitude":0.022676,"askPrice":4.34,"askSize":3000,"bidPrice":4.32,"bidSize":28000,"shortable":0,"etf":0,"ttmEps":-0.02685042212496696,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"listingDate":1634054400000,"adjPreClose":4.41,"openAndCloseTimeList":[[1734658200000,1734667200000],[1734670800000,1734681600000]],"volumeRatio":0.3890002505296542,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2492341153","title":"和誉-B：唐艳旻辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2492341153","media":"格隆汇资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492341153?lang=zh_cn&edition=full","pubTime":"2024-12-20 19:36","pubTimestamp":1734694583,"startTime":"0","endTime":"0","summary":"格隆汇12月20日丨和誉-B(02256.HK)公告，于2024年12月20日，唐艳旻女士因其须付出更多精力处理其他工作提呈辞任非执行董事之职，自2024年12月20日起生效，辞任后不再担任公司任何职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220193637a1fdae34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220193637a1fdae34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2492116911","title":"【券商聚焦】国元国际：和誉(02256)目前价值严重低估 长期看好其发展前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2492116911","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492116911?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:46","pubTimestamp":1734587163,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国元国际发研指，和誉 宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获中国国家药品监督管理局药品审评中心批准，开展治疗肝细胞癌的注册性临床研究。目前，晚期肝癌病人缺乏有效的治疗方案。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzgwMTczMTA1NDUyODEwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949962","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2488822045.USD","02256"],"gpt_icon":0},{"id":"2492255339","title":"和誉-B(02256)上涨5.11%，报4.73元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492255339","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492255339?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:38","pubTimestamp":1734493127,"startTime":"0","endTime":"0","summary":"12月18日，和誉-B(02256)盘中上涨5.11%，截至11:38，报4.73元/股，成交592.65万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/18113846524345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2492928113","title":"和誉-B盘中异动 临近午盘股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492928113","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492928113?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:38","pubTimestamp":1734493124,"startTime":"0","endTime":"0","summary":"2024年12月18日临近午盘11时38分，和誉-B股票出现异动，股价快速上涨5.11%。截至发稿，该股报4.730港元/股，成交量127.9万股，换手率0.19%，振幅6.89%。和誉-B股票所在的生物技术行业中，整体涨幅为0.23%。和誉-B公司简介：和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121811384495ea427d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121811384495ea427d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2492239940","title":"港股异动 | 和誉-B(02256)涨近4% 获CDE批准开展依帕戈替尼治疗肝细胞癌的注册性临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2492239940","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492239940?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:23","pubTimestamp":1734492207,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B涨近4%，截至发稿，涨3.78%，报4.67港元，成交额537.73万港元。这项研究将作为支持依帕戈替尼上市的关键依据，也标志着依帕戈替尼在晚期或不可切除肝细胞癌治疗领域迈出了重要的一步。另外，12月8日，公司公告在第66届美国血液学会年会上口头报告了匹米替尼治疗2L+慢性移植物抗宿主病的初步II期研究结果。尽管大多数入组患者尚未完成cGvHD缓解评估所需要的6个月治疗周期，但匹米替尼20mg QD治疗患者的初步ORR已经达到64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","CDE","BK1161","BK4017","LU2488822045.USD"],"gpt_icon":0},{"id":"2491690305","title":"港股公告掘金 | 华新水泥拟斥资约1.866 亿美元收购巴西四座骨料工厂","url":"https://stock-news.laohu8.com/highlight/detail?id=2491690305","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491690305?lang=zh_cn&edition=full","pubTime":"2024-12-16 22:27","pubTimestamp":1734359258,"startTime":"0","endTime":"0","summary":"【重大事项】石四药集团(02005)：富马酸伏诺拉生及盐酸决奈达隆获国家药监局批准登记成为在上市制剂使用的原料药远大医药(00512)：全球创新的治疗蠕形螨睑缘炎产品上市许可申请获中国药监局受理和誉-B(02256)：CDE批准开展依帕戈替尼(ABSK011)用于HCC患者的注册性临床研究华新水泥(06655)拟斥资约1.866 亿美元收购巴西四座骨料工厂翰森制药(03692)：B7-H3靶向抗体","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1225681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","HSTECH","YANG","02005","HSCEI","BK0186","BK0235","03692","BK1161","BK0028","06655","BK1191","LU2488822045.USD","02256","00512","LU2460026573.USD","BK1589","600801","BK1135","BK0188"],"gpt_icon":1},{"id":"2490638840","title":"和誉-B：匹米替尼CGVHD初步II期数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2490638840","media":"中金公司","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490638840?lang=zh_cn&edition=full","pubTime":"2024-12-12 00:00","pubTimestamp":1733932800,"startTime":"0","endTime":"0","summary":"尽管大多数入组患者尚未完成cGvHD缓解评估所需要的6 个月治疗周期，但匹米替尼20mg QD治疗患者的初步ORR已经达到64%。评论匹米替尼针对cGvHD的缓解率亮眼，且有潜力继续提升。根据ASH报告，46 名患者接受了匹米替尼5mg、10mg、15mg、20mg和25mg的治疗，患者此前中位系统治疗线数为4L。匹米替尼展现出良好的肺部缓解信号。匹米替尼安全耐受性良好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212110624a1e7e68c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241212110624a1e7e68c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02256","LU2488822045.USD"],"gpt_icon":0},{"id":"2490078184","title":"和誉-B(02256)：口服PD-L1小分子抑制剂ABSK043联合伏美替尼治疗非小细胞肺癌的 II期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2490078184","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490078184?lang=zh_cn&edition=full","pubTime":"2024-12-11 07:04","pubTimestamp":1733871884,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司附属和誉医药宣布已完成“一项评估ABSK043联合伏美替尼治疗 EGFR突变阳性的局部晚期或转移性非小细胞肺癌患者的有效性和安全性的II期开放性临床研究”的首例患者给药。ABSK043是由和誉医药自主研发的一款口服生物利用度好、高选择性、高活性的小分子PD-L1 抑制剂，目前正在开发用于治疗多种恶性肿瘤。ABSK043和伏美替尼的联合治疗，有望为EGFR突变的晚期肺癌患者带来更好的临床抗肿瘤疗效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","LU1169590202.USD","PD","BK1161","LU1169589451.USD","LU2488822045.USD","BK4023"],"gpt_icon":0},{"id":"2490762528","title":"和誉(02256.HK)附属于美国展示匹米替尼治疗研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2490762528","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490762528?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:05","pubTimestamp":1733706300,"startTime":"0","endTime":"0","summary":"和誉-B(02256.HK) 公布，附属公司上海和誉生物医药科技在第66届美国血液学会(ASH)年会上，以口头报告形式发布了匹米替尼(ABSK021)治疗既往一线，或多线治疗失败的慢性移植物抗宿主病患者的初步II期研究结果。公告指，尽管大多数入组患者尚未完成cGvHD缓解评估所需的6个月治疗周期，但是其中接受匹米替尼20毫克QD治疗患者亚组的初步数据显示ORR已达64%。(js/w)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211028115122826_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211028115122826_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1402559/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02256","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"2490769284","title":"和誉-B：和誉医药在ASH年会上展示匹米替尼治疗cGvHD的初步II期积极研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2490769284","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490769284?lang=zh_cn&edition=full","pubTime":"2024-12-09 08:16","pubTimestamp":1733703360,"startTime":"0","endTime":"0","summary":"　　和誉-B发布公告，公司的附属公司上海和誉生物医药科技有限公司在第66届美国血液学会年会上以口头报告形式发布了匹米替尼治疗既往一线或多线治疗失败的慢性移植物抗宿主病患者的初步II期研究结果。尽管大多数入组患者尚未完成cGvHD缓解评估所需的6个月治疗周期，但是其中接受匹米替尼20毫克QD 治疗患者亚组的初步数据显示ORR已达64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-12-09/doc-incyvhrw9800882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","02256","ASH","BK1161","BK1515","BK4109","BK1574","LU2463526074.USD","09939","LU2488822045.USD"],"gpt_icon":0},{"id":"2490763872","title":"智通港股早知道 | 央行时隔半年首次增持黄金 2024年冬季车市价格战降温","url":"https://stock-news.laohu8.com/highlight/detail?id=2490763872","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490763872?lang=zh_cn&edition=full","pubTime":"2024-12-09 06:55","pubTimestamp":1733698503,"startTime":"0","endTime":"0","summary":"中国央行时隔半年首次增持黄金中国央行： 中国11月末黄金储备7,296万盎司，10月末为7,280万盎司，此前央行连续六个月暂停增持黄金。超2亿人次 2024年澳门出入境通关人次创历史新高澳门特区政府治安警察局8日发布消息称，截至12月7日，今年澳门累计出入境人次超过2亿人次，创历年新高，与2023年全年1.8亿人次相比增加9.4%。降价幅度达到4.3%；常规燃油新车型和降价车型价格的平均降价1.34万元，平均降价幅度7.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","159831","YANG","HSCEI","LU2488822045.USD","BK1161","07226","02256"],"gpt_icon":0},{"id":"2489380507","title":"和誉附属公司展示匹米替尼治疗cGvHD初步研究结果，客观缓解率64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489380507","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489380507?lang=zh_cn&edition=full","pubTime":"2024-12-08 19:27","pubTimestamp":1733657275,"startTime":"0","endTime":"0","summary":"财中社12月8日电和誉-B（02256）发布公告，称其附属公司上海和誉生物医药科技有限公司在第66届美国血液学会年会上展示了匹米替尼（ABSK021）治疗慢性移植物抗宿主病（cGvHD）的初步II期研究结果。尽管大多数入组患者尚未完成为期6个月的治疗周期，接受匹米替尼20毫克QD治疗的患者亚组中，初步数据显示客观缓解率（ORR）达64%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412083262156025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2489738229","title":"和誉-B(02256)：和誉医药在第66届ASH年会上展示匹米替尼治疗cGvHD的初步II期积极研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489738229","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489738229?lang=zh_cn&edition=full","pubTime":"2024-12-08 19:19","pubTimestamp":1733656757,"startTime":"0","endTime":"0","summary":"尽管大多数入组患者尚未完成cGvHD缓解评估所需的6个月治疗周期，但是其中接受匹米替尼20毫克QD 治疗患者亚组的初步数据显示ORR已达64%。这些数据共同证明了匹米替尼治疗cGvHD相关的BOS的临床疗效。研究结果表明，匹米替尼在接受多种既往治疗的cGvHD患者中，表现出显著的临床疗效和良好的耐受性。基于最新的临床经验，匹米替尼可能为治疗cGvHD提供一种有前景的全新治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","ASH","02256","BK1574","LU2463526074.USD","BK1515","09939","BK1161","LU2488822045.USD","BK4109"],"gpt_icon":0},{"id":"2489758284","title":"和誉：ABSK043单药具有良好的安全性和抗肿瘤活性","url":"https://stock-news.laohu8.com/highlight/detail?id=2489758284","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489758284?lang=zh_cn&edition=full","pubTime":"2024-12-06 13:34","pubTimestamp":1733463254,"startTime":"0","endTime":"0","summary":"财中社12月6日电和誉-B（02256）发布自愿性公告，宣布其附属公司上海和誉生物医药科技有限公司在2024年欧洲肿瘤内科学会亚洲年会（ESMOAsia2024）上以口头报告形式展示了其自主研发的口服PD-L1抑制剂ABSK043治疗晚期实体瘤患者的最新一期研究结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412063261374835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2489427662","title":"和誉(02256)：已于欧洲肿瘤内科学会亚洲年会展示口服PD-L1抑制剂ABSK043的最新1期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489427662","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489427662?lang=zh_cn&edition=full","pubTime":"2024-12-06 12:26","pubTimestamp":1733459170,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和誉(02256)公告，公司之附属公司上海和誉生物医药科技有限公司（“和誉医药”）宣布，其已在于新加坡举办的2024年欧洲肿瘤内科学会亚洲年会（“ESMO Asia 2024”）上以口头报告形式展示其自主研发的口服PD-L1抑制剂ABSK043治疗晚期实体瘤患者的最新1期研究结果。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949131","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK1161","LU1169589451.USD","LU1169590202.USD","LU2488822045.USD","BK4023","02256"],"gpt_icon":0},{"id":"2489876422","title":"和誉-B(02256)：和誉医药以口头报告形式展示其口服PD-L1抑制剂 ABSK043的最新1期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2489876422","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489876422?lang=zh_cn&edition=full","pubTime":"2024-12-06 12:04","pubTimestamp":1733457895,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，该公司的附属公司上海和誉生物医药科技有限公司宣布，其已在于新加坡举办的2024年欧洲肿瘤内科学会亚洲年会上以口头报告形式展示其自主研发的口服PD-L1 抑制剂ABSK043治疗晚期实体瘤患者的最新1期研究结果。研究结果表明，在600mg-1000mg BID剂量组，ABSK043单药具有良好的安全性和抗肿瘤活性。这些发现将持续支持ABSK043在EGFR突变肺癌和各种其他实体瘤中的进一步研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","PD","BK1161","LU1169590202.USD","LU1169589451.USD","BK1515","BK1574","BK4023","159938","02256","09939"],"gpt_icon":0},{"id":"2489177366","title":"和誉-B(02256)下跌5.35%，报4.6元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2489177366","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489177366?lang=zh_cn&edition=full","pubTime":"2024-12-05 10:23","pubTimestamp":1733365389,"startTime":"0","endTime":"0","summary":"12月5日，和誉-B(02256)盘中下跌5.35%，截至10:23，报4.6元/股，成交1707.55万元。和誉开曼有限责任公司是一家专注于发现和开发创新小分子肿瘤治疗药物的生物制药公司，拥有十多个专注于精确肿瘤学和肿瘤免疫治疗的创新药物研发项目，其中五项已进入临床阶段。公司的主要战略方向是小分子肿瘤精准治疗、小分子肿瘤免疫治疗及其联合疗法的研究，以满足全球患者对癌症治疗的迫切需求。截至2024年中报，和誉-B营业总收入4.97亿元、净利润2.07亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/05102346039645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2488822045.USD","BK1161","02256"],"gpt_icon":0},{"id":"2489103679","title":"和誉-B盘中异动 急速下挫5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489103679","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489103679?lang=zh_cn&edition=full","pubTime":"2024-12-05 10:23","pubTimestamp":1733365381,"startTime":"0","endTime":"0","summary":"2024年12月05日早盘10时23分，和誉-B股票出现异动，股价快速下挫5.35%。截至发稿，该股报4.600港元/股，成交量377.2万股，换手率0.56%，振幅6.79%。和誉-B股票所在的生物技术行业中，整体跌幅为1.22%。和誉-B公司简介：和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK091是一种分子靶向候选产品,是FGFR亚型1、2及3的高效及选择性抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205102301a1d51a63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205102301a1d51a63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2488968203","title":"港股异动 | 和誉-B(02256)涨超3% 附属治疗实体瘤抑制剂获美国批准临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2488968203","media":"智通财经","labels":["executive","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488968203?lang=zh_cn&edition=full","pubTime":"2024-12-03 14:45","pubTimestamp":1733208332,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B(02256)涨超3%，截至发稿，涨3.16%，报4.9港元，成交额1898万港元。消息面上，和誉公告，12月3日，上海和誉生物医药科技有限公司今天宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131获得FDA的IND批准。此次获批的是在晚期实体瘤患者中开展I期临床试验，试验题为“一项评估ABSK131在晚期╱转移性实体瘤患者中的安全性、耐受性、药代动力学和初步有效性的1期、首次人体、多中心、开放性研究”。研究人群主要为抑癌基因MTAP缺失的患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1583","BK1141","BK1161","LU2488822045.USD","02256","BK1576"],"gpt_icon":0},{"id":"2488952976","title":"和誉附属公司获FDA批准开展ABSK131临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2488952976","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488952976?lang=zh_cn&edition=full","pubTime":"2024-12-03 14:09","pubTimestamp":1733206172,"startTime":"0","endTime":"0","summary":"财中社12月3日电和誉-B（02256）发布公告称，其附属公司上海和誉生物医药科技有限公司（公司）于2024年12月3日宣布，高选择性小分子PRMT5*MTA抑制剂ABSK131获得美国FDA的IND批准。这一批准将用于在晚期实体瘤患者中开展I期临床试验，主要研究抑癌基因MTAP缺失患者的安全性、耐受性、药代动力学及初步有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412033257675829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","BK1161","BK1576","02256","BK1583","03347","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":-0.0091},{"period":"1month","weight":-0.0023},{"period":"3month","weight":0.391},{"period":"6month","weight":0.391},{"period":"1year","weight":0.2056},{"period":"ytd","weight":0.189}],"compareEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0801},{"period":"6month","weight":0.0939},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1568}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家中国的临床阶段生物制药公司。该公司致力于发现及开发创新且差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011及ABSK091以及12款其他管线候选产品。ABSK011是一种有效的高选择性小分子成纤维细胞生长因子受体4（FGFR4）抑制剂。ABSK091是一种分子靶向候选产品，是FGFR亚型1、2及3的高效及选择性抑制剂。该公司的产品主要用于治疗肝细胞癌（HCC）、尿路上皮癌（UC）及胃癌（GC）。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.206623},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.021578},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.062878},{"month":4,"riseRate":0.333333,"avgChangeRate":0.018452},{"month":5,"riseRate":0,"avgChangeRate":-0.043841},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.013147},{"month":7,"riseRate":0.666667,"avgChangeRate":0.049332},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.050943},{"month":9,"riseRate":0.666667,"avgChangeRate":0.042883},{"month":10,"riseRate":0.666667,"avgChangeRate":0.004984},{"month":11,"riseRate":0.75,"avgChangeRate":0.204437},{"month":12,"riseRate":0,"avgChangeRate":-0.107354}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}